rs587781658
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000051.4(ATM):c.2284_2285delCT(p.Leu762ValfsTer2) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000185 in 1,461,354 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000051.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.2284_2285delCT | p.Leu762ValfsTer2 | frameshift_variant | Exon 15 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251234Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135804
GnomAD4 exome AF: 0.0000185 AC: 27AN: 1461354Hom.: 0 AF XY: 0.0000165 AC XY: 12AN XY: 727010
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:6
This sequence change creates a premature translational stop signal (p.Leu762Valfs*2) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is present in population databases (rs587781658, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia (PMID: 8789452, 8845835, 9463314, 21792198, 27484032). For these reasons, this variant has been classified as Pathogenic. -
- -
- -
Variant summary: ATM c.2284_2285delCT (p.Leu762ValfsX2) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 8e-06 in 251234 control chromosomes. c.2284_2285delCT has been widely reported in the literature in multiple individuals affected with Ataxia-Telangiectasia (example, Gilad_1996, Hacia_1998, Stankovic_1998, Jackson_2016). These data indicate that the variant is very likely to be associated with disease. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (n=7)/likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
- -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant deletes 2 nucleotides in exon 15 of the ATM gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in the homozygous state or in the compound heterozygous state with an additional pathogenic ATM variant in individuals affected with ataxia-telangiectasia (PMID: 8789452, 8845835, 9463314, 21792198). This variant has also been reported in individuals affected with breast cancer, prostate cancer, or familial colorectal cancer type X (PMID: 28486781, 28657667, 28779002, 29566657, 32984025, 33471991). This variant has been identified in 2/251234 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The c.2284_2285delCT pathogenic mutation, located in coding exon 14 of the ATM gene, results from a deletion of two nucleotides at nucleotide positions 2284 to 2285, causing a translational frameshift with a predicted alternate stop codon (p.L762Vfs*2). This mutation has been reported in either a homozygous or compound heterozygous state in multiple individuals affected with ataxia-telangiectasia (AT) (Byrd PJ et al. Hum. Mol. Genet. 1996 Jan;5:145-9; Gilad S et al. Hum. Mol. Genet. 1996 Apr;5:433-9; Stankovic T et al. Am. J. Hum. Genet. 1998 Feb;62:334-45; Kraus M et al. J Clin Immunol, 2014 Jul;34:561-72; Yu H et al. J. Allergy Clin. Immunol. 2016 Oct;138:1142-1151.e2). This mutation has also been reported in a heterozygous state in multiple breast cancer patients as well as prostate and colorectal cancer patients (Lolas Hamameh S et al. Int J Cancer. 2017 Aug 15;141(4):750-756; Pilie PG et al. Cancer. 2017 Oct 15;123(20):3925-3932; Decker B et al. J Med Genet. 2017 Nov;54(11):732-741; Wang YA et al. BMC Cancer. 2018 Mar 22;18(1):315; Xu Y et al. Front Oncol, 2020 Sep;10:1603; Dorling et al. N Engl J Med. 2021 02;384:428-439). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Familial cancer of breast Pathogenic:2
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
- -
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Pathogenic:1
PVS1; PM3; PM5_SUP -
not provided Pathogenic:1
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 8789452, 15928302, 26045716, 9259193, 27484032, 26786923, 8845835, 29922827, 9463314, 21792198, 20852892, 1551665, 14695997, 21459046, 28779002, 28152038, 27304073, 29566657, 28486781, 28657667, 32853339, 30549301, 35022142, 33804961, 33471991, 32984025, 24789685, 35261632, 34771661, 35741767, 34196900, 34887416, 26896183) -
Malignant tumor of breast Pathogenic:1
The ATM p.Leu762ValfsX2 variant was identified in 2 of 4040 proband chromosomes (frequency: 0.0005) from individuals or families with breast cancer and severe combined immune deficiency and was not identified in 3994 control chromosomes from healthy individuals (Yu 2016, Thompson 2016). The variant was also identified in dbSNP (ID: rs587781658) as “With Pathogenic allele”. In addition, the variant was identified in the ClinVar database as pathogenic by Ambry Genetics, Invitae, GeneDx, Genetics Services Laboratory, University of Chicago and as likely pathogenic by Counsyl; and in the Clinvitae database as pathogenic by Invitae. The variant was further reported 4X in the LOVD 3.0 database. The variant was not identified in the following databases: COGR, Cosmic, MutDB, ATM-LOVD, the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, and the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.2284_2285del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 762 and leads to a premature stop codon at position 763. This alteration is then predicted to result in a truncated or absent protein and loss of function. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at